Pro Medicus (ASX:PME) share price eyes all-time high
This ASX health imaging company is on the verge of breaking a record.
Aaron Teboneras has been a Motley Fool contributor since early August 2020. After graduating from RMIT University with a Business degree, Aaron spent most of his years either travelling or working in various industries. Aaron’s most notable appointments include National Australia Bank, and Computershare where he discovered his passion for the Australian sharemarket. Outside of researching and writing for Motley Fool, Aaron enjoys trekking on adventures across the world and learning new life skills.
Latest posts by Aaron Teboneras (see all)
Pro Medicus (ASX:PME) share price sinks despite new deal
Aaron Teboneras | May 13, 2021 10:42am |
More on:
The
Pro Medicus Limited(ASX: PME) share price is a poor performer so far on Thursday despite the company providing a positive update. In early morning trade, the health imaging company’s shares are fetching $40.05, down 1.26%.
What was announced?
Investors have been selling Pro Medicus shares regardless of the company’s announced contract win.
According to its release, Pro Medicus’ wholly-owned United Stated subsidiary, Visage Imaging Inc., has signed a deal with The University of Vermont Health Network Inc (UVM).
Under the agreement, Pro Medicus will deploy its Visage 7 Enterprise Imaging Platform across 6 hospitals operated by UVM. It is expected that, once the system is fully functional, a unified diagnostic imaging platform will run across the network. This replaces the existing multiple legacy PACS platforms that are currently being used.
Australia’s sharemarket is trading lower; Xero profit soars on strong subscriber numbers; Orica first-half profit down 54pc, warns on H2; GrainCorp upgrades guidance on strong margins; iron ore hits record. Follow the latest here.